Antidepressant News and Research

RSS

Antidepressants are medicines that treat depression. Your doctor can prescribe them for you. They can improve your mood, sleep, appetite and concentration. It may take several weeks for them to help. There are several types of antidepressants. You and your doctor may have to try several before finding what works best for you.

Thermodynamic insights into histamine H1 receptor ligand binding

G-protein-coupled receptors (GPCRs) are one of the largest families of cell surface proteins in the human body that recognize hormones, neurotransmitters, and drugs.

13 Feb 2026

Discontinuing antidepressants during pregnancy raises psychiatric risks

Pregnant patients who stopped taking their antidepressant medication during pregnancy were almost twice as likely to experience a mental health emergency compared with pregnant patients who continued taking their prescription, according to new research presented today at the Society for Maternal-Fetal Medicine (SMFM) 2026 Pregnancy Meeting.

11 Feb 2026

Review links betel nut addiction to cancer, heart disease, and metabolic risks

This review examines the epidemiology, health risks, neurobiological mechanisms, and emerging treatments related to betel nut addiction worldwide. It highlights strong links with oral cancer, cardiometabolic disease, and addiction pathways while noting limited established therapies and the need for coordinated public health strategies.

11 Feb 2026

Electroacupuncture relieves pain-induced anxiety through prefrontal neural circuits

Neuropathic pain, caused by injury or disease of the somatosensory nervous system, is a major clinical challenge and often evolves into a chronic condition.

7 Feb 2026

Antidepressant use does not worsen early outcomes after traumatic brain injury

Taking certain antidepressants at the time of a traumatic brain injury (TBI) is not associated with an increased risk of death, brain surgery or longer hospital stays, according to a study published on January 28, 2026, in Neurology, the medical journal of the American Academy of Neurology.

28 Jan 2026

Vagus nerve stimulation shows lasting benefit in treatment-resistant depression

Findings reveal that vagus nerve stimulation leads to lasting benefits in treatment-resistant depression, improving function and quality of life over two years.

16 Jan 2026

New chemistry revives neurokinin-1 receptor as depression treatment target

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major depressive disorder.

14 Jan 2026

Implanted vagus nerve stimulation device offers lasting relief for severe depression

About 20% of U.S. adults experience major depression in their lifetime. For most people, symptoms improve within a few treatment attempts, but up to one-third of patients have treatment-resistant depression, for which standard antidepressant medication or psychotherapy isn't enough.

13 Jan 2026

Breastfeeding is linked to lower depression and anxiety years later

A decade-long study links breastfeeding to lower anxiety and depression in mothers, suggesting long-term mental health benefits beyond the postnatal period.

13 Jan 2026

Physical activity shows comparable benefits to therapy for treating depression

Exercise may reduce symptoms of depression to a similar extent as psychological therapy, according to an updated Cochrane review. When compared with antidepressant medication, exercise also showed a similar effect, but the evidence was of low certainty.

7 Jan 2026

Charting brain cell epigenomics to reveal origins of psychiatric disorders

In a revealing Genomic Press Interview published today in Genomic Psychiatry, Dr. Maria Margarita Behrens recounts an extraordinary scientific journey that wound through four countries and multiple disciplines before arriving at fundamental questions about how the brain develops and what goes wrong in psychiatric disorders.

6 Jan 2026

Depression links to chronic headaches through weight and diet, not physical activity alone

Depression was associated with a higher likelihood of chronic headaches in Iranian adults, with statistical models identifying body mass index and dietary iron intake as partial mediators. Physical activity was linked to depression but did not independently mediate headache outcomes, highlighting interconnected, non-causal pathways.

1 Jan 2026

Why the form of vitamin B12 you take may matter more than your intake

This comprehensive review examines vitamin B12 absorption, physiological roles, deficiency states, and dietary sources, with particular attention to differences between natural and synthetic forms. The authors conclude that while all B12 forms raise circulating levels, methylcobalamin may offer advantages in specific clinical contexts, especially where absorption or metabolic conversion is impaired.

10 Dec 2025

Targeting inflammation may reduce depression severity and anhedonia

Naoise Mac Giollabhui, PhD, of the Department of Psychiatry at Mass General Brigham, is the lead author of a paper published in American Journal of Psychiatry, "Effect of anti-inflammatory treatment on depressive symptom severity and anhedonia in depressed individuals with elevated inflammation: Systematic review and meta-analysis of randomized controlled trials." Richard Liu, PhD, of the Department of Psychiatry at Mass General Brigham, is the senior author.

10 Dec 2025

Laughing gas shows fast antidepressant effects in early clinical trials

A systematic review and meta-analysis in eBioMedicine shows that nitrous oxide can rapidly reduce depressive symptoms within hours, particularly at higher doses, but effects are short-lived after single treatments. Repeated dosing appears to extend and strengthen antidepressant benefits, although the current evidence is based on small, early-phase trials with limited long-term safety data.

8 Dec 2025

Young Australians are staying on antidepressants for longer than ever

Long-term antidepressant use in Australia increased steadily between 2014 and 2023, with the largest relative rise seen among adolescents and young adults aged 10 to 24 years. Treatment duration also lengthened over time, while apparent dose reduction efforts remained limited, raising concerns about deprescribing practices.

7 Dec 2025

Study finds sharp rise in long-term antidepressant use among young Australians

Long-term antidepressant use in Australia has risen steadily over the past decade, with the largest increase seen in young people aged 10-24, where rates have more than doubled.

2 Dec 2025

Short-term nitrous oxide treatment could benefit patients with major depressive disorder

Patients with major depressive disorder, including those who have not responded to first-line antidepressants, may benefit from short-term nitrous oxide treatment, a major meta-analysis led by the University of Birmingham has found.

1 Dec 2025

Parental postpartum depression linked to higher autism risk

Findings reveal a strong link between parental postpartum depression and autism risk, stressing the importance of mental health support for new parents.

17 Nov 2025

The caffeine conundrum in rapid depression treatments

Perhaps the most intriguing implication of recent breakthrough research lies in an unexpected connection: the most rigorous mechanistic dissection of rapid antidepressant action identifies adenosine as the critical mediator, yet adenosine receptors are the primary target of caffeine, the world's most widely consumed psychoactive substance.

11 Nov 2025